Literature DB >> 16714570

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.

Sandra Hervas-Stubbs1, Laleh Majlessi, Marcela Simsova, Jana Morova, Marie-Jesus Rojas, Clémence Nouzé, Priscille Brodin, Peter Sebo, Claude Leclerc.   

Abstract

TB10.4 is a newly identified antigen of Mycobacterium tuberculosis recognized by human and murine T cells upon mycobacterial infection. Here, we show that immunization with Mycobacterium bovis BCG induces a strong, genetically controlled, Th1 immune response against TB10.4 in mice. BALB/c and C57BL/6 strains behave as high and low responders to TB10.4 protein, respectively. The TB10.4:74-88 peptide was identified as an immunodominant CD4+ T-cell epitope for H-2d mice. Since recent results, as well as the present study, have raised interest in TB10.4 as a subunit vaccine, we analyzed immune responses induced by this antigen delivered by a new vector, the adenylate cyclase (CyaA) of Bordetella pertussis. CyaA is able to target dendritic cells and to deliver CD4+ or CD8+ T-cell epitopes to the major histocompatibility complex class II/I molecule presentation pathways, triggering specific Th1 or cytotoxic T-lymphocyte (CTL) responses. Several CyaA harboring either the entire TB10.4 protein or various subfragments containing the TB10.4:20-28 CTL epitope were shown to induce TB10.4-specific Th1 CD4+ and CD8+ T-cell responses. However, none of the recombinant CyaA, injected in the absence of adjuvant, was able to induce protection against M. tuberculosis infection. In contrast, TB10.4 protein administered with a cocktail of strong adjuvants that triggered a strong Th1 CD4+ T-cell response induced significant protection against M. tuberculosis challenge. These results confirm the potential value of the TB10.4 protein as a candidate vaccine and show that the presence of high frequencies of CD4+ T cells specific to this strong immunogen correlates with protection against M. tuberculosis infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714570      PMCID: PMC1479244          DOI: 10.1128/IAI.02086-05

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens.

Authors:  J Karttunen; S Sanderson; N Shastri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

2.  Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming.

Authors:  Géraldine Schlecht; Jirina Loucka; Hossain Najar; Peter Sebo; Claude Leclerc
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

3.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.

Authors:  P A Selwyn; D Hartel; V A Lewis; E E Schoenbaum; S H Vermund; R S Klein; A T Walker; G H Friedland
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

4.  Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis.

Authors:  L Brandt; T Oettinger; A Holm; A B Andersen; P Andersen
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

5.  Recognition of mycobacterial antigens delivered by genetically detoxified Bordetella pertussis adenylate cyclase by T cells from cattle with bovine tuberculosis.

Authors:  H Martin Vordermeier; Marcela Simsova; Katalin A Wilkinson; Robert J Wilkinson; R Glyn Hewinson; Peter Sebo; Claude Leclerc
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Adjuvant modulation of immune responses to tuberculosis subunit vaccines.

Authors:  E B Lindblad; M J Elhay; R Silva; R Appelberg; P Andersen
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

7.  Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.

Authors:  Priscille Brodin; Laleh Majlessi; Roland Brosch; Debbie Smith; Gregory Bancroft; Simon Clark; Ann Williams; Claude Leclerc; Stewart T Cole
Journal:  J Infect Dis       Date:  2004-06-04       Impact factor: 5.226

8.  Mapping of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG.

Authors:  K Huygen; E Lozes; B Gilles; A Drowart; K Palfliet; F Jurion; I Roland; M Art; M Dufaux; J Nyabenda
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; M M Goldstein; K J Triebold; B Koller; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

10.  Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.

Authors:  F R Carbone; M J Bevan
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  44 in total

1.  Complexes of streptavidin-fused antigens with biotinylated antibodies targeting receptors on dendritic cell surface: a novel tool for induction of specific T-cell immune responses.

Authors:  Ondrej Stanek; Irena Linhartova; Laleh Majlessi; Claude Leclerc; Peter Sebo
Journal:  Mol Biotechnol       Date:  2012-07       Impact factor: 2.695

Review 2.  General and molecular microbiology and microbial genetics in the IM CAS.

Authors:  Jan Nešvera
Journal:  J Ind Microbiol Biotechnol       Date:  2010-11-18       Impact factor: 3.346

3.  Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.

Authors:  Xindong Teng; Maopeng Tian; Jianrong Li; Songwei Tan; Xuefeng Yuan; Qi Yu; Yukai Jing; Zhiping Zhang; Tingting Yue; Lei Zhou; Xionglin Fan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

5.  Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.

Authors:  Daniel O Villarreal; Jewell Walters; Dominick J Laddy; Jian Yan; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Lactation-Based Maternal Educational Immunity Crosses MHC Class I Barriers and Can Impart Th1 Immunity to Th2-Biased Recipients.

Authors:  Mrinal K Ghosh; H Konrad Muller; Ameae M Walker
Journal:  J Immunol       Date:  2017-07-26       Impact factor: 5.422

7.  Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.

Authors:  Carlos R Zárate-Bladés; Rodrigo F Rodrigues; Patricia R M Souza; Wendy M Rios; Luana S Soares; Rogério S Rosada; Izaíra T Brandão; Ana Paula Masson; Elaine M Floriano; Simone G Ramos; Celio L Silva
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

8.  Role of Metal-Dependent Regulation of ESX-3 Secretion in Intracellular Survival of Mycobacterium tuberculosis.

Authors:  Emir Tinaztepe; Jun-Rong Wei; Jenelle Raynowska; Cynthia Portal-Celhay; Victor Thompson; Jennifer A Philips
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

Review 9.  ESX secretion systems: mycobacterial evolution to counter host immunity.

Authors:  Matthias I Gröschel; Fadel Sayes; Roxane Simeone; Laleh Majlessi; Roland Brosch
Journal:  Nat Rev Microbiol       Date:  2016-09-26       Impact factor: 60.633

10.  CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.

Authors:  Tara Elvang; Jan P Christensen; Rolf Billeskov; Truc Thi Kim Thanh Hoang; Peter Holst; Allan Randrup Thomsen; Peter Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.